Marc Miquel Moltó Abad I am a biologist with experience in both clinical and preclinical research on lysosomal storage diseases. I am intrigued by the clinical complexity of these rare diseases. Their low incidence in the population, the limited knowledge about their pathophysiology and the limitations of their current treatment are important points that needs to be investigated. I am very interested in nanotechnology application as a tool to improve the treatment of these diseases as well as the life quality of these patients. Institutions of which they are part Predoctoral researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Marc Miquel Moltó Abad LinkedIn Twitter Orcid Email Institutions of which they are part Predoctoral researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca I am a biologist with experience in both clinical and preclinical research on lysosomal storage diseases. I am intrigued by the clinical complexity of these rare diseases. Their low incidence in the population, the limited knowledge about their pathophysiology and the limitations of their current treatment are important points that needs to be investigated. I am very interested in nanotechnology application as a tool to improve the treatment of these diseases as well as the life quality of these patients.
I have experience in cell culture, in vitro and in vivo assays and the monitoring of clinical trials. Regarding basic research, I have participated in projects ranging from the field of cancer and telomere dysfunction, to projects about the study of nanoparticles application in order to improve the treatment of a rare metabolic disease (Fabry's disease). In 2013 I got my Biology’s degree from the Universitat Autònoma de Barcelona and in 2015 I completed an official master's degree in Cytogenetics and Reproductive Biology at the same university where I was able to work on my cell culture skills (derivative publication in Oncotarget). Subsequently, I started to work as a research technician in the Rare Diseases Unit of the Vall d'Hebron University Hospital in Barcelona (2016-2019), where I collaborated in the coordination of research projects and clinical trials focused on a group of rare diseases called lysosomal storage diseases. Consequently, I am a co-author of different scientific publications (8), in specialized journals (Mol Genet Metab, J Clin Med, Orphanet J Rare Dis, J Bone Min Res). In 2020, I began my journey as a predoctoral researcher in the Delivery and Targeting research group testing nanometric systems for the improvement of current treatment of Fabry disease. As a result, I am a co-author of a review paper (WIRES) and a scientific publication (J Extracel Ves).
Projects CancerScan: Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology IP: Santiago Ramon y Cajal Agüeras Collaborators: Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Marc Miquel Moltó Abad, Gisela Espriu Aguado, Sonia Borao Arriazu Funding agency: EUROPEAN COMMISSION Funding: 609600 Reference: CANCERSCAN_RAMON Y CAJAL_EC/PATHFINDER_OPEN2024 Duration: 01/08/2025 - 31/07/2028 ERDERA: European Rare Disease Research Alliance IP: M Mar Mañu Pereira Collaborators: Sara Isabel Reidel , Sara Isabel Reidel , Miguel Chillon Rodriguez, Esther García Pagès, Raquel Mosull del Campo, Raquel Mosull del Campo, Simon Schwartz Navarro, Agustín Arasanz Duque, Sandra Mancilla Zamora, Anna Collado Gimbert, Marc Miquel Moltó Abad, Ángela Menárguez López, Ángela Menárguez López, Ángela Menárguez López, Claire Diot Funding agency: EUROPEAN COMMISSION Funding: 771525 Reference: ERDERA_MAÑU_EC_HLTH2023-DISEASE-07-01/2023 Duration: 01/09/2024 - 31/08/2031 TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido i Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Teresa Macarulla Mercadé, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno Garcia del Blanco, Ana Vivancos Prellezo, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Sandra Mancilla Zamora, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Gabriela Guillén Burrieza, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Jaume Capdevila Castillon, Nicolás Miguel Fissolo , Maria Nazarena Pizzi, Paolo Giovanni Nuciforo, Tian Tian, Andrea Guala , Juan Pablo Betancur Rengifo Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027 EVERETT: Engineered mesenchymal stromal cell Extracellular Vesicles for immunomodulatory biotherapy and Enzyme REplacemenT Therapy IP: - Collaborators: Marc Miquel Moltó Abad Funding agency: Agence Nationale de la Recherche Funding: 0.01 Reference: EVERETT_ANR-BIOPNSE2020 Duration: 01/11/2022 - 31/10/2025 Pagination Current page 1 Page 2 Next page › Last page »
